I started working on the development of amino salicylates in 1983. At that time it was deter mined that sulfasalazine-5aminosalicylic acid (5ASA) linked to sulfapyridine by an azo bondwas primarily a prodrug that delivered 5ASA into the colon to treat ulcerative colitis. At about the same time preliminary evidence suggested that delivery of 5ASA into the small bowel could be therapeutic for Crohn's disease. In either case, the key was luminal delivery that minimized systemic absorption, since the effect of 5ASA appeared to be topical on the epithelium and absorbed 5ASA seemed to be inactivated by Nacetylation and urinary excretion.
Concern was expressed regarding the sys temic effects of high doses of 5ASA because aspirin (acetylsalicylic acid) and related sali cylates have a wellrecognized potential to cause nephrotoxicity in both animals and humans. In animal studies the nephrotoxic dose of 5ASA approximated the 4-5 g dose potentially used in humans, and there was a single case of nephrotoxicity reported in a Danish patient treated with 3 g of a sustainedrelease mesala zine formulation. Thus, in advisory meetings on the development of mesalazine, Europeans, in particular, were concerned about using a dose of mesalazine higher than that delivered by full dose sulfasalazine (sulfasalazine is approxi mately 40% 5ASA, hence 4-6 g of sulfasalazine delivers the equivalent of 1.6-2.4 g of mesalazine into the colon). Further concern existed over the increased levels of mesalazine absorption associated with smallbowel delivery.
The subsequent development programs for both delayedrelease (pHsensitive) and sustainedrelease (ethylcellulose) formulations of mesalazine extensively explored the risk of nephrotoxicity for doses up to 4-4.8 g. Large clinical trials in patients with ulcerative colitis or Crohn's disease failed to demonstrate evidence of doserelated nephrotoxicity and numerous book chapters and journal articles described mesalazine as safe for the kidneys. Nevertheless, sporadic cases of nephrotoxicity continued to occur in patients treated with mesalazine, most often reported by nephrologists, while the preponderance of gastrointestinal literature continued to proclaim the safety of mesala zine and the absence of doserelated renal effects.
Nevertheless, the US FDA placed a warning within the prescribing information for mesa lazine products that stated "It is recommended that all patients have an evaluation of renal function prior to initiation of therapy and periodi cally while on treatment. Unfortunately, my own writings have reflected the general message that mesalazine was safe for the kidneys at doses up to 4.8 g necessary to treat patients with IBD and failed to empha size the small, but welldescribed risk of idio syncratic interstitial nephritis and renal failure, as outlined by others (Inflamm Bowel Dis [2007] 13: [629] [630] [631] [632] [633] [634] [635] [636] [637] [638] . A number of malpractice cases in the US have pertained to the prescriber's failure to monitor renal function in patients who developed nephrotoxicity secondary to 5ASA treatment. So, despite the general safety of aminosaliyclates and the lack of doserelated nephrotoxicity, I recommend that prescribers should be aware of the small risk of idiosyncratic nephritis attributable to any 5ASA product, assess the patient's baseline renal function, and monitor their blood urea nitrogen and creati nine concentrations within the first 6 months of therapy and yearly thereafter. 
Mea culpa

